Stock Market & Financial Investment News

News Breaks February 14, 2013 09:11 EDT TEVA, SHPG Teva's generic version of Shire's Adderall XR approved by FDA Teva (TEVA) announced that the FDA has approved its Abbreviated New Drug Application for the generic version of Shire (SHPG)’s Adderall XR Capsules, 5mg, 10mg, 15mg, 20mg, 25mg and 30 mg capsules for the treatment of attention deficit hyperactivity disorder. Adderall XR had annual sales, including brand and generic sales, of approximately $2B in the United States. News For TEVA;SHPG From The Last 14 Days Check below for free stories on TEVA;SHPG the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 20, 2013 07:27 EDT SHPG American Psychiatric Association to host annual meeting Subscribe for More Information 07:01 EDT SHPG Sangamo BioSciences announces positive data for Vivo Protein platform Sangamo BioSciences (SGMO) announced the presentation of new data demonstrating the successful application of Sangamo's proprietary In Vivo Protein Replacement Platform to produce therapeutically relevant levels of Factor VIII in a mouse model. Sangamo has partnered with Shire (SHPG) to develop ZFP Therapeutics for both hemophilia A and B using this approach. 06:30 EDT SHPG Leerink estimates Shire takeout value at least $110 per share Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. 06:25 EDT SHPG Shire may return cash to thwart takeover, Daily Mail reports Subscribe for More Information May 14, 2013 07:24 EDT SHPG EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. May 13, 2013 09:44 EDT TEVA Several companies reportedly interested in buying Adcock Ingram, Globes says Subscribe for More Information 07:49 EDT TEVA FDA decision on Opana a modest positive for Impax, says Leerink Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. May 10, 2013 10:00 EDT SHPG On The Fly: Analyst Downgrade Summary Subscribe for More Information 10:00 EDT TEVA On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. 05:42 EDT SHPG Shire downgraded to Neutral from Overweight at JPMorgan May 9, 2013 16:35 EDT TEVA Teva initiated with an Outperform at BMO Capital Subscribe for More Information 12:24 EDT SHPG Shire unit wins patent trial against Watson regarding LIALDA Shire (SHPG), announces that its subsidiary, Shire Development, has prevailed in its litigation against Watson Pharmaceuticals, Watson Laboratories-Florida, Watson Pharma. and Watson Laboratories in connection with their Abbreviated New Drug Application for a generic version of Shire's LIALDA delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. Following a five day bench trial in the Southern District of Florida, Judge Middlebrooks issued a ruling upholding the validity of the patent covering LIALDA, US Patent No. 6,773,720, and holding that the proposed ANDA formulation infringes the claims of that patent. Accordingly, Judge Middlebrooks confirmed that Shire is entitled to an injunction, which he will issue separately, which prohibits the FDA from approving the ANDA formulation until the expiration of the '720 patent. 10:17 EDT SHPG Shire trades higher in London amid takeover chatter, Guardian says Subscribe for More Information May 8, 2013 12:03 EDT TEVA Teva says data demonstrates ovulatory effect of investigational contraceptive Subscribe for More Information 10:26 EDT TEVA Alexza deal with Teva could be worth $12 per share or more, says Roth Capital Subscribe for More Information 09:06 EDT TEVA Alexza Pharmaceuticals to host conference call Subscribe for More Information 08:33 EDT TEVA Teva, Alexza announce Teva's license to market Adasuve in the U.S. Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical (TEVA), and Alexza Pharmaceuticals (ALXA) announced that the companies have entered into an exclusive U.S. license and supply agreement for Adasuve inhalation powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Teva will be responsible for all U.S. commercial and clinical activities for Adasuve, including U.S. post-approval clinical studies, and has gained rights to conduct additional clinical trials of Adasuve for potential new indications in neurological disorders. Alexza will be responsible for manufacturing and supplying Adasuve to Teva for commercial sales and clinical trials. Under the terms of the license and supply agreement, Alexza will receive an upfront cash payment of $40M and is eligible to receive up to $195M in additional milestone payments, based upon successful completion of the ADASUVE post-approval studies in the U.S. and achieving net sales targets. In addition, Teva will make tiered, royalty payments based on net commercial sales of Adasuve. May 7, 2013 11:50 EDT TEVA Teva rival receives patent for once a month Copaxone Subscribe for More Information May 6, 2013 07:18 EDT TEVA American Congress of Obstetrics and Gynecology to hold annual meeting Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.